Mycotic aneurysm formation after bacillus Calmette–Guérin instillation for recurrent bladder cancer

Rohailla et al cite that intravesical therapy involving bacillus Calmette-Guerin (BCG) is standard of care for high-grade, noninvasive urothelial carcinoma, with reported cure rates higher than 70%. Systemic infection occurs in less than 5% of patients and likely involves hematogenous spread from th...

Full description

Saved in:
Bibliographic Details
Published in:Canadian Medical Association journal (CMAJ) 2018-04, Vol.190 (15), p.E467-E471
Main Authors: Rohailla, Sagar, MD MSc, Kitchlu, Abhijat, MD, Wheatcroft, Mark, MD MBChB, Razak, Fahad, MD MSc
Format: Article
Language:English
Subjects:
Abdomen
Aneurysms
Back pain
BCG
Bladder cancer
Cancer therapies
Cardiovascular disease
Care and treatment
Case studies
Complications and side effects
Coronary vessels
Diagnosis
Dosage and administration
Drug therapy
Family medical history
Hospitals
Immunotherapy
Infected aneurysm
Infections
Internal Medicine
Kidney diseases
Laboratories
Medical imaging
Medical research
Medicine
NMR
Nuclear magnetic resonance
Patient outcomes
Practice
Risk factors
Surgery
Systematic review
Urine
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Rohailla et al cite that intravesical therapy involving bacillus Calmette-Guerin (BCG) is standard of care for high-grade, noninvasive urothelial carcinoma, with reported cure rates higher than 70%. Systemic infection occurs in less than 5% of patients and likely involves hematogenous spread from the instillation site, promoted by local cystitis, traumatic catheterization or a bleeding site in the bladder. Infection of an aortic aneurysm is uncommon, but should be considered when patients present with back pain after BCG therapy.
ISSN:0820-3946
1488-2329
DOI:10.1503/cmaj.171214